Improving COVID-19 Treatment & Vaccine Development by Modulating the Immune Response: Applying Single-Cell Proteomics 

James R. Heath, PhD, President of the Institute for Systems Biology will discuss key single-cell learnings and applications from the large Seattle-based academic pharmaceutical consortium committed to defining molecular mechanisms of SARS-CoV-2 infection and identifying potential prognostic immune biomarkers. Stacey Willard, PhD, from IsoPlexis will discuss how functional phenotyping individual immune cells using IsoPlexis technology edges researchers closer to predicting the risk for severe disease. 

The Scientist Creative Services Team
Jun 10, 2020

FREE Webinar

Thursday, July 2, 2020
3:30 - 5:00 PM, Eastern Standard Time

Register Now

Several biotech and pharmaceutical companies have joined forces to investigate the molecular mechanisms of SARS-CoV-2 infection and to identify targets for medicines and vaccines. As members of the Seattle Consortium, IsoPlexis, Merck, and the Institute for Systems Biology play key roles in the search for COVID-19 prognostic immune biomarkers. In this webinar sponsored by IsoPlexis, James Heath from the Institute for Systems Biology and Stacey Willard from IsoPlexis will discuss how functional phenotyping individual immune cells using IsoPlexis technology edges researchers closer to predicting the risk for severe disease.

Topics to be covered

  • Proteomic and genomic insights into COVID-19
  • Mapping functional immune responses at the single-cell and serum level to study COVID-19
  • Using single-cell proteomics to study how to create a balanced and durable immune response in COVID-19 patients and assist efforts to create future vaccines and therapies

Register Now

Meet the Speakers:

James R. Heath, PhD
President and Professor
Institute for Systems Biology, Seattle


Stacey Willard, PhD
Product Manager
IsoPlexis